Type 2 Diabetes Drugs And Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Type 2 Diabetes Drugs and Devices Market Report is Segmented by Product Type (Management Devices [Insulin Pumps, Insulin Syringes, and More], Monitoring Devices [Self-Monitoring Blood Glucose, and More], Drugs [Oral Anti-Diabetic Drugs, Insulins, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Type 2 Diabetes Drugs And Devices Market Size and Share

Type 2 Diabetes Drugs And Devices Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Type 2 Diabetes Drugs And Devices Market with other markets in Healthcare Industry

Type 2 Diabetes Drugs And Devices Market Analysis by Mordor Intelligence

The global Type 2 diabetes drugs and devices market stands at USD 94.77 billion in 2025 and is on track to reach USD 132.08 billion by 2030, expanding at a 6.87% CAGR. Growth reflects the rapid clinical shift toward GLP-1 receptor agonists, broader reimbursement for continuous glucose monitoring (CGM), and sustained investment in digital-first distribution models. Demand also rises in tandem with the escalating prevalence of obesity and sedentary lifestyles, while manufacturers re-engineer supply chains to prioritize high-value injectables over legacy human insulin lines. Intensifying competition from technology firms and consumer electronics brands accelerates device innovation, and regulatory focus on cybersecurity pushes connected-pump developers to harden software architectures.

Key Report Takeaways

  • By product category, drugs led with 52.76% revenue share in 2024; monitoring devices are forecast to expand at a 10.16% CAGR to 2030.
  • By distribution channel, hospital pharmacies held 44.53% of the Type 2 diabetes drugs and devices market share in 2024, while online pharmacies record the highest projected CAGR at 10.67% through 2030.
  • By geography, North America commanded 39.78% of the Type 2 diabetes drugs and devices market in 2024; Asia-Pacific is poised for the fastest regional expansion at 9.34% CAGR to 2030. 

Segment Analysis

By Product Type: Drugs Sustain Dominance

Drugs controlled 52.76% of the Type 2 diabetes drugs and devices market in 2024. GLP-1 receptor agonists and dual-incretin compounds, such as tirzepatide, have redrawn competitive lines by delivering glycemic, cardiovascular, and renal benefits in a single weekly injection. Insulin innovation continues as Eli Lilly pursues once-weekly formulations, a shift designed to ease adherence burdens. SGLT2 inhibitors complement GLP-1 therapies in combination regimens that aim to delay renal decline. Meanwhile, biosimilar entrants preparing for post-2026 patent expiries are expected to widen access and temper prices. Pharmaceutical R&D increasingly targets triple-agonist profiles, seeking still broader metabolic control windows. Despite device advances, clinician preference for proven drug classes maintains elevated demand, securing the segment’s lead through the forecast horizon.

Management Devices Gain Ground

Insulin-delivery technologies evolve toward low-burden formats. CeQur’s three-day wearable patch exemplifies simplified dosing for Type 2 diabetes patients requiring multiple daily injections. Insulet secured FDA clearance in August 2024 for SmartAdjust, the first automated insulin-delivery algorithm explicitly indicated for Type 2 diabetes. Medtronic’s Simplera Sync CGM, paired with MiniMed 780G, also won FDA approval, fusing disposable sensors with adaptive pumps. Such closed-loop ecosystems address glycemic variability while reducing finger-stick dependence. Device makers court payer support by evidencing reduced hospitalization costs from hypoglycemia or diabetic ketoacidosis events. Although cost remains a barrier, device innovation is set to expand its addressable base beyond intensive Type 1 therapy.

Monitoring Devices: CGM Outpaces Finger-Stick Testing

CGM advances drive a double-digit CAGR, positioning monitoring technologies as the fastest-growing component of the Type 2 diabetes drugs and devices market. Medicare’s 2023 policy eliminated restrictive calibration rules, enabling Dexcom, Abbott, and Medtronic to target millions of insulin-naïve users. Dexcom’s over-the-counter Stelo is expected to trigger retail-channel expansion once commercially launched. Implantable sensors with six-month wear times are now under CMS coverage review, potentially redefining convenience benchmarks. Meanwhile, consumer-wearable players seek noninvasive optical approaches, though accuracy hurdles persist. Widespread CGM adoption feeds data back to AI-powered decision dashboards, which fine-tune dose recommendations and alert clinicians to early-stage complications.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Digital Transformation Accelerates Online Growth

Hospital pharmacies accounted for 44.53% of the Type 2 diabetes drugs and devices market share in 2024, bolstered by established physician networks and prior-authorization expertise. Online pharmacies, however, post a 10.67% CAGR through 2030 as telehealth scripts migrate to mail-order fulfillment. LillyDirect illustrates the model, linking independent telehealth providers with home delivery and medication counseling. Retail chains respond by layering clinical services—HbA1c testing, nutrition coaching, and virtual endocrinology visits—to safeguard foot traffic. Regulatory bodies monitor direct-to-consumer dispensing for continuity-of-care risks, yet broader digital health acceptance suggests online channels will capture an increasing slice of routine refills.

Market Segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America commanded 39.78% of the Type 2 diabetes drugs and devices market in 2024, benefiting from broad insurance coverage and a proactive regulatory stance. Medicare’s CGM expansion and FDA clearances for over-the-counter sensors and AID systems sustain regional technology leadership. Novo Nordisk allotted USD 4.1 billion to new North Carolina capacity, while Eli Lilly earmarked USD 5.3 billion for Indiana facilities, ensuring supply lines for GLP-1 injectables. The FDA’s cybersecurity advisories also guide device design, reinforcing patient safety standards.

Asia-Pacific delivers the fastest regional CAGR at 9.34% through 2030 as urbanization, dietary shifts, and lower BMI diagnostic thresholds fuel demand. China’s 233 million patients and three-tier treatment architecture highlight systemic urgency. Local guidelines increasingly endorse GLP-1/SGLT2 combination therapy and CGM for high-risk cohorts, fostering rapid uptake. Multinationals align with domestic manufacturers to navigate volume-based procurement rules—Novo Nordisk secured streamlined approval for semaglutide in 2024, affirming this approach.

Europe leverages centralized purchasing and robust clinical guidelines to maintain substantial market presence. The European Medicines Agency’s January 2024 clinical trial update foregrounded personalized cardiometabolic endpoints, steering R&D pipelines accordingly. Coordinated responses to GLP-1 shortages, including distribution caps, demonstrate advanced demand-management capabilities. Sanofi’s EUR 1.3 billion Frankfurt insulin expansion, slated for 2029, underscores continued investment in injectable drug security across the continent.

Geography growth
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competition is moderate yet intensifying as traditional pharmaceutical incumbents diversify into data-rich digital services while tech firms angle for noninvasive monitoring niches. Medtronic’s decision to spin off its USD 2.76 billion diabetes arm signals a push toward focused AID innovation with a workforce exceeding 8,000 specialists. Novo Nordisk’s reprioritization away from human insulin pens confirms the market’s pivot to GLP-1 dominance, whereas Dexcom’s generative-AI advisory engine—built on Google Cloud’s Vertex AI—illustrates the race to convert glucose data into actionable insights.

Abbott’s Libre platform remains pivotal, with the Medtronic tie-up promising to connect 6 million Libre users to pump networks. Embecta targets underserved high-dose Type 2 diabetes patients with 300-unit patch pumps, challenging pump incumbents on reservoir capacity. Consumer-electronics giants eye the space: Apple’s optical-sensor patents and Samsung’s millimeter-wave prototypes hint at future noninvasive entrants, although regulatory clearance remains distant. Compliance lapses carry reputational risk, as exemplified by FDA warning letters to CGM manufacturers; firms with robust quality systems may gain a credibility edge.

Type 2 Diabetes Drugs And Devices Industry Leaders

  1. Abbott

  2. Medtronic

  3. Novo Nordisk

  4. Eli Lilly

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
Type 2 Diabetes Drugs And Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: Tandem Diabetes Care and Abbott agree to integrate AID platforms with glucose-ketone sensors, aiming to curb diabetic ketoacidosis in closed-loop systems.
  • June 2025: Eli Lilly files for approval of once-weekly insulin after favorable phase 3 data, seeking to improve adherence for basal therapy.
  • May 2025: Medtronic announces intent to spin off its diabetes unit into a USD 2.76 billion standalone company focused on AID and smart MDI systems.
  • April 2025: FDA approves pairing of Medtronic Simplera Sync CGM with MiniMed 780G pump, forming an integrated, finger-stick-free AID solution.

Table of Contents for Type 2 Diabetes Drugs And Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence Of Diabetes Type -2, Obesity & Sedentary Lifestyles
    • 4.2.2 Rapid Uptake Of GLP-1 Receptor Agonists
    • 4.2.3 Expansion Of Reimbursement For Continuous Glucose Monitoring
    • 4.2.4 Pharma–Tech Data-Sharing Partnerships Lowering Time-To-Market For Combo Devices
    • 4.2.5 Government And Public Initiatives Taken To Improve Health And Support Of Employers To Curb Diabetes
    • 4.2.6 Integration Of Closed-Loop Insulin Delivery Into Consumer Wearables
  • 4.3 Market Restraints
    • 4.3.1 High Cost Of Novel GLP-1 Drugs & Smart Pumps
    • 4.3.2 Stringent Regulatory Safety Monitoring For SGLT2 Inhibitors
    • 4.3.3 Global Glass-Vial Shortage Delaying Injectable Launches
    • 4.3.4 Cyber-Security Vulnerabilities In Connected Insulin Pumps
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Product Type
    • 5.1.1 Management Devices
    • 5.1.1.1 Insulin Pumps
    • 5.1.1.2 Insulin Syringes
    • 5.1.1.3 Insulin Cartridges
    • 5.1.1.4 Disposable Pens
    • 5.1.1.5 Jet Injectors
    • 5.1.2 Monitoring Devices
    • 5.1.2.1 Self-Monitoring Blood Glucose (SMBG)
    • 5.1.2.2 Continuous Glucose Monitoring (CGM)
    • 5.1.3 Drugs
    • 5.1.3.1 Oral Anti-Diabetics
    • 5.1.3.1.1 Biguanides
    • 5.1.3.1.2 SGLT2 Inhibitors
    • 5.1.3.1.3 DPP-4 Inhibitors
    • 5.1.3.2 Insulins
    • 5.1.3.2.1 Basal (Long-acting)
    • 5.1.3.2.2 Bolus (Rapid/Short-acting)
    • 5.1.3.3 Non-Insulin Injectables
    • 5.1.3.3.1 GLP-1 Receptor Agonists
    • 5.1.3.4 Combination Drugs
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.4.1 Novo Nordisk A/S
    • 6.4.2 Eli Lilly and Company
    • 6.4.3 Sanofi
    • 6.4.4 Abbott Laboratories
    • 6.4.5 Medtronic plc
    • 6.4.6 Roche Holding AG
    • 6.4.7 Pfizer Inc.
    • 6.4.8 Takeda Pharmaceutical Co.
    • 6.4.9 AstraZeneca plc
    • 6.4.10 Merck & Co., Inc.
    • 6.4.11 Boehringer Ingelheim GmbH
    • 6.4.12 Bristol Myers Squibb Co.
    • 6.4.13 Novartis AG
    • 6.4.14 Janssen Pharmaceuticals (J&J)
    • 6.4.15 Astellas Pharma Inc.
    • 6.4.16 Dexcom Inc.
    • 6.4.17 Insulet Corporation
    • 6.4.18 Tandem Diabetes Care Inc.
    • 6.4.19 Becton, Dickinson and Company (BD)
    • 6.4.20 Ypsomed AG

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Type 2 Diabetes Drugs And Devices Market Report Scope

Type 2 diabetes is a condition that causes the level of sugar in the blood to become too high. The Type 2 diabetes drugs and devices market is segmented into management devices (insulin pumps, insulin syringes, insulin cartridges, disposable pens, and jet injectors), monitoring devices (self-monitoring blood glucose and continuous glucose monitoring), drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments.

By Product Type Management Devices Insulin Pumps
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Monitoring Devices Self-Monitoring Blood Glucose (SMBG)
Continuous Glucose Monitoring (CGM)
Drugs Oral Anti-Diabetics Biguanides
SGLT2 Inhibitors
DPP-4 Inhibitors
Insulins Basal (Long-acting)
Bolus (Rapid/Short-acting)
Non-Insulin Injectables GLP-1 Receptor Agonists
Combination Drugs
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Management Devices Insulin Pumps
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Monitoring Devices Self-Monitoring Blood Glucose (SMBG)
Continuous Glucose Monitoring (CGM)
Drugs Oral Anti-Diabetics Biguanides
SGLT2 Inhibitors
DPP-4 Inhibitors
Insulins Basal (Long-acting)
Bolus (Rapid/Short-acting)
Non-Insulin Injectables GLP-1 Receptor Agonists
Combination Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current value of the Type 2 diabetes drugs and devices market?

The market is valued at USD 94.77 billion in 2025 and is projected to hit USD 132.08 billion by 2030.

2. Which drug class is driving recent growth?

GLP-1 receptor agonists—now approved for cardiovascular risk reduction—are the primary catalyst for prescription growth and manufacturer capacity expansion.

3. Why are continuous glucose monitors growing so quickly?

Medicare and other payers have eased coverage rules, extending CGM access to millions of insulin-naïve Type 2 diabetes patients and fueling double-digit device CAGR

4. How are online pharmacies affecting distribution dynamics?

Telehealth platforms such as LillyDirect streamline direct-to-consumer dispensing, helping online channels grow at a 10.67% CAGR through 2030.

5. Which region will grow the fastest through 2030?

Asia-Pacific, propelled by rising prevalence and expanding healthcare access, is forecast to register a 9.34% CAGR—outpacing all other regions.

Page last updated on: June 25, 2025

Type 2 Diabetes Drugs And Devices Market Report Snapshots